SCHEMBL4280093

SCHEMBL4280093

Cc1ccc(C(=O)N2CCN(c3cc(C(C)(C)C)cc(C(C)(C)C)c3)CC2)c(C)c1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 8/20 0.56
HTT P42858 5/20 0.56
KDM4E B2RXH2 3/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
KMT2A Q03164 3/20 0.48
MEN1 O00255 2/20 0.48
MAPK1 P28482 1/20 0.48
GFER P55789 1/20 0.48
ALDH1A1 P00352 4/20 0.47
MAPT P10636 3/20 0.47
TSHR P16473 3/20 0.47
HPGD P15428 1/20 0.47
POLB P06746 1/20 0.45
HCRTR1 O43613 1/20 0.44
HCRTR2 O43614 1/20 0.44
GLA P06280 1/20 0.43
MCL1 Q07820 1/20 0.43
DRD2 P14416 1/20 0.43
DRD3 P35462 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4272429 0.77 SLC6A9 (0.53) KMT2AMEN1GFER
SCHEMBL4276681 0.76 SMN1; SMN2 (0.63) LMNAHTTKDM4ESMN1; SMN2KMT2A
SCHEMBL4271305 0.76 MEN1 (0.44) LMNAHTTKDM4ESMN1; SMN2KMT2A
SCHEMBL4274664 0.76 HSP90AA1 (0.59) LMNAHTTKDM4ESMN1; SMN2KMT2A
SCHEMBL24910640 0.76 LMNA (0.53) LMNAHTTKDM4ESMN1; SMN2KMT2A
SCHEMBL11961209 0.76 HRH4 (0.54) LMNAHTTKDM4ESMN1; SMN2KMT2A
SCHEMBL4271969 0.76 CA12 (0.49) LMNAHTTKDM4EMAPK1GFER
SCHEMBL4277884 0.76 ALDH1A1 (0.59) LMNAHTTKDM4ESMN1; SMN2KMT2A
SCHEMBL4273078 0.76 LMNA (0.60) LMNAHTTKDM4ESMN1; SMN2KMT2A
SCHEMBL15692312 0.76 HTT (0.62) LMNAHTTKDM4ESMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090270413-A1 DI-T-BUTYLPHENYL PIPERAZINES AS CALCIUM CHANNEL BLOCKERS ZALICUS PHARMACEUTICALS LTD. (CA) 2009-10-29 US disclosed
US-20090270413-A1 DI-T-BUTYLPHENYL PIPERAZINES AS CALCIUM CHANNEL BLOCKERS ZALICUS PHARMACEUTICALS LTD. (CA) 2009-10-29 US disclosed
US-20090270413-A1 DI-T-BUTYLPHENYL PIPERAZINES AS CALCIUM CHANNEL BLOCKERS ZALICUS PHARMACEUTICALS LTD. (CA) 2009-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270413-A1 DI-T-BUTYLPHENYL PIPERAZINES AS CALCIUM CHANNEL BLOCKERS CACNA1G, CACNA1C, CACNA1I LMNA 2209/4885HTT 2262/4885KDM4E 3805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.